Viewing the Eph receptors with a focus on breast cancer heterogeneity.

Aberrant expression of different family members of the Eph/ephrin system, which comprises the Eph receptors (Ephs) and their ligands (ephrins), has been implicated in various malignancies including breast cancer. The latter presents as a heterogeneous disease with diverse molecular, morphologic and clinical behavior signatures. This review reflects the existing Eph/ephrin literature while focusing on breast cancer heterogeneity. Hormone positive, HER2 positive and triple negative breast cancer (TNBC) cell lines, xenografts/mutant animal models and patient samples are examined separately as, in humans, they represent entities with differences in prognosis and treatment. EphA2, EphB4 and EphB6 are the members most extensively studied in breast cancer. Existing research points to the potential use of various Eph/ephrin members as biomarkers for assessing prognosis and selecting the most suitable therapeutic strategies in variable clinical scenarios, also for overcoming drug resistance, in the era of breast cancer heterogeneity.

• Publication year

  2018

• Venue

  Cancer Letters

• Publication date

  2018-10-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.canlet.2018.07.030PMID 30055288
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Development and Evaluation of Antibody Proteomics Technology for Rapid and Comprehensive Identification of Potential Biomarkers and Therapeutic Targets.

  2018cited by this paper
• Juxtacrine Signaling Inhibits Antitumor Immunity by Upregulating PD-L1 Expression.

  2018cited by this paper
• Inhibition of HDACs-EphA2 Signaling Axis with WW437 Demonstrates Promising Preclinical Antitumor Activity in Breast Cancer

  2018cited by this paper
• Breast cancer intratumour heterogeneity: current status and clinical implications

  2018cited by this paper
• De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017

  2018cited by this paper
• EPHB6 augments both development and drug sensitivity of triple-negative breast cancer tumours

  2018cited by this paper
• Reduction of Circulating Cancer Cells and Metastases in Breast-Cancer Models by a Potent EphA2-Agonistic Peptide–Drug Conjugate

  2018cited by this paper
• Eph A10-modified pH-sensitive liposomes loaded with novel triphenylphosphine–docetaxel conjugate possess hierarchical targetability and sufficient antitumor effect both in vitro and in vivo

  2018cited by this paper
• YSA-conjugated mesoporous silica nanoparticles effectively target EphA2-overexpressing breast cancer cells

  2018cited by this paper
• Erythropoietin-producing hepatocellular A6 overexpression is a novel biomarker of poor prognosis in patients with breast cancer.

  2018cited by this paper
• A phase 1 study evaluating the safety, pharmacology and preliminary activity of MM-310 in patients with solid tumors.

  2018cited by this paper
• Differential Expression Patterns of Eph Receptors and Ephrin Ligands in Human Cancers

  2018cited by this paper
• Overcoming Multidrug Resistance by Codelivery of MDR1-Targeting siRNA and Doxorubicin Using EphA10-Mediated pH-Sensitive Lipoplexes: In Vitro and In Vivo Evaluation.

  2018cited by this paper
• Reduced EphB6 protein in gastric carcinoma and associated lymph nodes suggests EphB6 as a gastric tumor and metastasis inhibitor

  2017cited by this paper
• Targeting EphA2 impairs cell cycle progression and growth of basal-like/triple-negative breast cancers

  2017cited by this paper
• EphA2 gene targeting using neutral liposomal small interfering RNA (EPHARNA) delivery: A phase I clinical trial.

  2017cited by this paper
• Loss of the EPH receptor B6 contributes to colorectal cancer metastasis

  2017cited by this paper
• Androgen-deprivation therapy with enzalutamide enhances prostate cancer metastasis via decreasing the EPHB6 suppressor expression.

  2017cited by this paper
• Ephs and ephrins.

  2017cited by this paper
• Breast Cancer—Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual

  2017cited by this paper
• Transforming Growth Factor-beta Regulation of Ephrin Type-A Receptor 4 Signaling in Breast Cancer Cellular Migration

  2017cited by this paper
• Intratumor heterogeneity predicts metastasis of triple-negative breast cancer

  2017cited by this paper
• Claudin-Low Breast Cancer; Clinical & Pathological Characteristics

  2017cited by this paper
• Isoform expression patterns of EPHA10 protein mediate breast cancer progression by regulating the E-Cadherin and β-catenin complex

  2017cited by this paper
• Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer.

  2017cited by this paper
• The receptor tyrosine kinase EphA2 promotes glutamine metabolism in tumors by activating the transcriptional coactivators YAP and TAZ

  2017cited by this paper
• Steps forward for cancer precision medicine

  2017cited by this paper
• Tumor Heterogeneity in Breast Cancer

  2017cited by this paper
• New Developments in Breast Cancer and Their Impact on Daily Practice in Pathology.

  2017cited by this paper
• Intratumoral heterogeneity of macrophages and fibroblasts in breast cancer is associated with the morphological diversity of tumor cells and contributes to lymph node metastasis.

  2017cited by this paper
• Comparing Breast Cancer Multiparameter Tests in the OPTIMA Prelim Trial: No Test Is More Equal Than the Others.

  2016cited by this paper
• EPH/ephrin profile and EPHB2 expression predicts patient survival in breast cancer

  2016cited by this paper
• Biology and Management of Patients With Triple-Negative Breast Cancer.

  2016cited by this paper
• KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study.

  2016cited by this paper
• Pooled Analysis of the Prognostic Relevance of Circulating Tumor Cells in Primary Breast Cancer

  2016cited by this paper
• Prognostic value of circulating tumor cells in metastatic breast cancer: a systemic review and meta-analysis

  2016cited by this paper
• Risk Stratification and Intrinsic Subtype Classification of Breast Cancer: a Multi-Parameter Test to Rule Them All?

  2016cited by this paper
• Targeting synthetic lethality between the SRC kinase and the EPHB6 receptor may benefit cancer treatment

  2016cited by this paper
• Tumor-infiltrating lymphocytes in breast cancer predict the response to chemotherapy and survival outcome: A meta-analysis

  2016cited by this paper
• Novel anti-EPHA2 antibody, DS-8895a for cancer treatment

  2016cited by this paper
• The intrinsically kinase-inactive EPHB6 receptor predisposes cancer cells to DR5-induced apoptosis by promoting mitochondrial fragmentation

  2016cited by this paper
• EPHA7 and EPHA10 Physically Interact and Differentially Co-localize in Normal Breast and Breast Carcinoma Cell Lines, and the Co-localization Pattern Is Altered in EPHB6-expressing MDA-MB-231 Cells.

  2016cited by this paper
• Phosphoproteomic analysis of interacting tumor and endothelial cells identifies regulatory mechanisms of transendothelial migration

  2016cited by this paper
• Evaluation of Breast Cancer Stem Cells and Intratumor Stemness Heterogeneity in Triple-negative Breast Cancer as Prognostic Factors

  2016cited by this paper
• The Ephrin-A1/EPHA2 Signaling Axis Regulates Glutamine Metabolism in HER2-Positive Breast Cancer.

  2016cited by this paper
• Clinical Significance of EphB4 and EphB6 Expression in Human Malignant and Benign Thyroid Lesions

  2016cited by this paper
• Subclonal diversification of primary breast cancer revealed by multiregion sequencing

  2015cited by this paper
• Proteotranscriptomic Profiling of 231-BR Breast Cancer Cells: Identification of Potential Biomarkers and Therapeutic Targets for Brain Metastasis*

  2015cited by this paper
• Clinical implications of the intrinsic molecular subtypes of breast cancer.

  2015cited by this paper
• miR-200a inhibits migration of triple-negative breast cancer cells through direct repression of the EPHA2 oncogene.

  2015cited by this paper
• Eph receptor tyrosine kinases in cancer stem cells.

  2015cited by this paper
• The 2014 Society of Surgical Oncology Susan G. Komen for the Cure Symposium: Triple-Negative Breast Cancer

  2015cited by this paper
• Eph receptors and ephrins: therapeutic opportunities.

  2015cited by this paper
• Anti-EFNA4 Calicheamicin Conjugates Effectively Target Triple-Negative Breast and Ovarian Tumor-Initiating Cells to Result in Sustained Tumor Regressions

  2015cited by this paper
• Crucial roles of RSK in cell motility by catalysing serine phosphorylation of EphA2

  2015cited by this paper
• Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer.

  2015cited by this paper
• Differential expression of neurogenes among breast cancer subtypes identifies high risk patients

  2015cited by this paper
• Global cancer statistics, 2012

  2015cited by this paper
• Triple-negative Breast Carcinoma: Morphologic and Molecular Subtypes

  2015cited by this paper
• Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015

  2015cited by this paper
• Dual targeting for metastatic breast cancer and tumor neovasculature by EphA2-mediated nanocarriers.

  2015cited by this paper
• The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014.

  2015cited by this paper
• The origin of breast tumor heterogeneity

  2015cited by this paper
• A breast cancer stem cell niche supported by juxtacrine signalling from monocytes and macrophages

  2014cited by this paper
• EphA2 Promotes Infiltrative Invasion of Glioma Stem Cells in vivo through Crosstalk with Akt and Regulates Stem Properties

  2014cited by this paper
• Mesenchymal to amoeboid transition is associated with stem-like features of melanoma cells

  2014cited by this paper
• EFNA3 long noncoding RNAs induced by hypoxia promote metastatic dissemination

  2014cited by this paper
• Eph receptor and ephrin function in breast, gut, and skin epithelia

  2014cited by this paper
• Ephrin (Eph) receptor A1, A4, A5 and A7 expression in human non-small cell lung carcinoma: associations with clinicopathological parameters, tumor proliferative capacity and patients’ survival

  2014cited by this paper
• Prospective evaluation of the conversion rate in the receptor status between primary breast cancer and metastasis: results from the GEICAM 2009-03 ConvertHER study

  2014cited by this paper
• Breast cancer intra-tumor heterogeneity

  2014cited by this paper
• Ephrin Receptor (Eph) -A1, -A2, -A4 and -A7 Expression in Mobile Tongue Squamous Cell Carcinoma: Associations with Clinicopathological Parameters and Patients Survival

  2014cited by this paper
• Overexpression of EphB4 in the mammary epithelium shifts the differentiation pathway of progenitor cells and promotes branching activity and vascularization

  2014cited by this paper
• EphB6 promotes anoikis by modulating EphA2 signaling.

  2014cited by this paper
• Role of the EphB2 receptor in autophagy, apoptosis and invasion in human breast cancer cells.

  2014cited by this paper
• Modulation of liver-intestine cadherin (Cadherin 17) expression, ERK phosphorylation and WNT signaling in EPHB6 receptor-expressing MDA-MB-231 cells.

  2014cited by this paper
• Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.

  2014cited by this paper
• Ephrin receptor A10 is a promising drug target potentially useful for breast cancers including triple negative breast cancers.

  2014cited by this paper
• JNK signaling mediates EPHA2-dependent tumor cell proliferation, motility, and cancer stem cell-like properties in non-small cell lung cancer.

  2014cited by this paper
• Eph receptor signaling and ephrins.

  2013cited by this paper
• Receptor tyrosine kinases with intracellular pseudokinase domains.

  2013cited by this paper
• Expression of Eph receptor A10 is correlated with lymph node metastasis and stage progression in breast cancer patients

  2013cited by this paper
• Therapeutic targeting of EPH receptors and their ligands

  2013cited by this paper
• Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.

  2013cited by this paper
• EphB4 Tyrosine Kinase Stimulation Inhibits Growth of MDA-MB-231 Breast Cancer Cells in a Dose and Time Dependent Manner

  2013cited by this paper
• EphA3 maintains tumorigenicity and is a therapeutic target in glioblastoma multiforme.

  2013cited by this paper
• Eph receptor B4 is a regulator of estrogen receptor alpha in breast cancer cells

  2013cited by this paper
• Attenuation of Eph Receptor Kinase Activation in Cancer Cells by Coexpressed Ephrin Ligands

  2013cited by this paper
• Enhanced expression of EphrinB1 is associated with lymph node metastasis and poor prognosis in breast cancer

  2013cited by this paper
• The molecular diversity of Luminal A breast tumors

  2013cited by this paper
• Update on triple-negative breast cancer: prognosis and management strategies

  2012cited by this paper
• The EphA2 receptor drives self-renewal and tumorigenicity in stem-like tumor-propagating cells from human glioblastomas.

  2012cited by this paper
• Regulation of tumor initiation and metastatic progression by Eph receptor tyrosine kinases.

  2012cited by this paper
• Comprehensive molecular portraits of human breast tumors

  2012cited by this paper
• WHO classification of tumours of the breast

  2012cited by this paper
• Evidence for a dual function of EphB4 as tumor promoter and suppressor regulated by the absence or presence of the ephrin‐B2 ligand

  2012cited by this paper
• Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors

  2012cited by this paper
• Eph receptors and ephrins as targets for cancer therapy

  2012cited by this paper
• EphrinA1–EphA2 interaction‐mediated apoptosis and FMS‐like tyrosine kinase 3 receptor ligand‐induced immunotherapy inhibit tumor growth in a breast cancer mouse model

  2012cited by this paper
• Basal Breast Cancer: A Complex and Deadly Molecular Subtype

  2012cited by this paper

• EphA2-targeted NIR-I/II fluorescent probe for specific imaging of colorectal cancer.

  2025cites this paper
• Tumor Innervation: From Bystander to Emerging Therapeutic Target for Cancer

  2025cites this paper
• Diversity of Intercellular Communication Modes: A Cancer Biology Perspective

  2024cites this paper
• Immunohistochemical expression of ephrin receptors in neuroendocrine neoplasms: a case-series of gastroenteropancreatic neuroendocrine neoplasms and a systematic review of the literature

  2024cites this paper
• Discrepancies in Hormone Receptor and HER2 Expression between Malignant Serous Effusions and Paired Tissues from Primary or Recurrent Breast Cancers

  2023cites this paper
• Expression of EGFR, PD‐L1, and the mismatch repair proteins before and following therapy in malignant serous effusions with metastatic high‐grade serous tubo‐ovarian carcinoma

  2023cites this paper
• Crosstalk between the peripheral nervous system and breast cancer influences tumor progression.

  2022cites this paper
• HOXA1, a breast cancer oncogene.

  2022cites this paper
• Signals transduced by Eph receptors and ephrin ligands converge on MAP kinase and AKT pathways in human cancers.

  2022cites this paper
• Biomarkers expression among paired serous ovarian cancer primary lesions and their peritoneal cavity metastases in treatment‐naïve patients: A single‐center study

  2022cites this paper
• EPHA2, EPHA4, and EPHA7 Expression in Triple-Negative Breast Cancer

  2022cites this paper
• Loss of EphA7 Expression in Basal Cell Carcinoma by Hypermethylation of CpG Islands in the Promoter Region

  2022cites this paper
• EPH/Ephrin-Targeting Treatment in Breast Cancer: A New Chapter in Breast Cancer Therapy

  2022cites this paper
• EphA2 recognizes Dermatophagoidespteronyssinus to mediate airway inflammation in asthma.

  2022cites this paper
• HOXA1 Is an Antagonist of ERα in Breast Cancer

  2021cites this paper
• Evaluating Infectious, Neoplastic, Immunological, and Degenerative Diseases of the Central Nervous System with Cerebrospinal Fluid-Based Next-Generation Sequencing

  2021cites this paper
• Discovery and Pharmacological Evaluation of STEAP4 as a Novel Target for HER2 Overexpressing Breast Cancer

  2021cites this paper
• MicroRNA-497-5p Is Downregulated in Hepatocellular Carcinoma and Associated with Tumorigenesis and Poor Prognosis in Patients

  2021cites this paper
• From genetic data and structures to drug development: New approaches to target Eph receptors

  2021cites this paper
• Role of CNK1, Ephrin B1, GPR19 and SMURF1 in breast cancer early diagnosis, metastasis and drug resistance

  2021cites this paper
• Heterogeneity of estrogen receptor based on 18F-FES PET imaging in breast cancer patients

  2021cites this paper
• Long Noncoding RNA OIP5-AS1 Promotes the Progression of Liver Hepatocellular Carcinoma via Regulating the hsa-miR-26a-3p/EPHA2 Axis

  2020cites this paper
• EphB6 Regulates TFEB-Lysosomal Pathway and Survival of Disseminated Indolent Breast Cancer Cells

  2020cites this paper
• Thiadiazole derivatives as anticancer agents

  2020cites this paper
• Evaluation of EphB4 as Target for Image-Guided Surgery of Breast Cancer

  2020cites this paper
• Optimization of stereospecific targeting technique for selective production of monoclonal antibodies against native ephrin type-A receptor 2.

  2020cites this paper
• Catalytically inactive receptor tyrosine kinase PTK7 activates FGFR1 independent of FGF

  2019cites this paper
• Serine-Arginine Protein Kinase 1 (SRPK1) as a Prognostic Factor and Potential Therapeutic Target in Cancer: Current Evidence and Future Perspectives

  2019cites this paper
• A Tyrosine Kinase Expression Signature Predicts the Post-Operative Clinical Outcome in Triple Negative Breast Cancers

  2019cites this paper